Aura Biosciences, Inc. (AURA)
Nasdaq · Healthcare · Biotechnology
$6.22+2.13%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $645M
- 52-week range
- $4.73 – $9.54
- 52-week change
- +2.87%
- EPS (trailing)
- −$1.75
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$106M
- Diluted EPS
- −$1.76
- Free cash flow
- −$85.2M
From the company’s annual report on SEC EDGAR.
About Aura Biosciences, Inc.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Headquarters: Boston, United States · 113 employees · aurabiosciences.com